AtaiBeckleySTU:B72 51 Current Ratio is 10.02 as of Mar. 2026, which is 9% below its 10-year median of 10.96. GuruFocus rates STU:B72 with a GF Score™ of 51/100 and a GF Value™ of €6.32. The stock has 4 warning signs investors should review. Among 1,417 Biotechnology companies, AtaiBeckley ranks better than 77.91% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. AtaiBeckley's current ratio for the quarter that ended in Mar. 2026 was 10.02.
AtaiBeckley has a current ratio of 10.02. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for AtaiBeckley's Current Ratio or its related term are showing as below:
STU:B72'
s Current Ratio Range Over the Past 10 Years
Min: 3.21 Med: 10.96 Max: 32.26
Current: 10.02
During the past 7 years, AtaiBeckley's highest Current Ratio was 32.26. The lowest was 3.21. And the median was 10.96.
STU:B72's Current Ratio is ranked better than 77.91% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs STU:B72: 10.02
AtaiBeckley (STU:B72) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
AtaiBeckley Current Ratio Related Terms
AtaiBeckley Current Ratio Historical Data
* Premium members only.
The historical data trend for AtaiBeckley's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:B72 vs GLUE, NUVB, BHVN: Current Ratio Comparison
For the Biotechnology subindustry, AtaiBeckley's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AtaiBeckley Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AtaiBeckley's Current Ratio distribution charts can be found below:
* The bar in red indicates where AtaiBeckley's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AtaiBeckley (STU:B72) has a Current Ratio of 10.02 as of Mar. 2026. This is near median its historical median of 10.96. Over the past decade, AtaiBeckley's Current Ratio has ranged from 3.21 to 32.26. According to the industry distribution chart, AtaiBeckley ranks #313 out of 1417 companies in the Biotechnology industry, placing it in the top 22.1%.
Is AtaiBeckley's Current Ratio too high?
AtaiBeckley's current Current Ratio of 10.02 is near median its 10-year median of 10.96. Over the past 10 years, this metric has ranged from a low of 3.21 to a high of 32.26. The Biotechnology industry median Current Ratio is 3.89. AtaiBeckley's value of 10.02 is 157.6% above this industry median. Based on the distribution chart, AtaiBeckley ranks #313 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AtaiBeckley has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does AtaiBeckley's Current Ratio compare to GLUE and NUVB?
According to the Biotechnology industry distribution chart, AtaiBeckley ranks #313 out of 1417 companies for Current Ratio. This places AtaiBeckley in the top 22% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. AtaiBeckley's value of 10.02 is 157.6% above this benchmark. Historically, AtaiBeckley's own Current Ratio has ranged from 3.21 to 32.26 over the past decade. While the company's 10-year median is 10.96 vs. the industry median of 3.89, AtaiBeckley has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AtaiBeckley's current Current Ratio of 10.02 is 157.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AtaiBeckley's current Current Ratio is 10.02, which is near median its own 10-year median of 10.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AtaiBeckley stock overvalued right now?
AtaiBeckley (STU:B72) has a current Current Ratio of 10.02. The stock's GF Value™ is €6.32, compared to a current price of €3.45 — trading 45.5% below its estimated fair value. The current Current Ratio is 10.02, which is near median its 10-year median of 10.96 and 157.6% above the Biotechnology industry median of 3.89. AtaiBeckley's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For AtaiBeckley (STU:B72), the current Current Ratio is 10.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AtaiBeckley (STU:B72) Overvalued in 2026?
Based on GuruFocus' analysis, AtaiBeckley stock appears to be undervalued.
The current stock price of €3.45 is trading 45.5% below its estimated GF Value™ of €6.32.
Key valuation signals for STU:B72:
Current Ratio: 10.02 (near median its 10-year median of 10.96)
GF Value™: €6.32 vs. price of €3.45 (45.5% below fair value)
Industry Position: 157.6% above the Biotechnology median (#313 of 1417)
No single metric tells the full story. See the STU:B72 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
51GF Score
Get the complete analysis for STU:B72
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:B72 has been successfully added to your 
